Acute Coronary Syndromes: Diagnosis and Management, Part II

Amit Kumar, MD, and Christopher P. Cannon, MD

On completion of this article, you should be able to: (1) identify the optimal reperfusion strategy for ST-segment elevation myocardial infarction in a given clinical scenario and recognize the importance of adjunctive pharmacological therapies, (2) list the various stress test methods for detection of significant coronary artery stenoses, and (3) discuss the relative risks and benefits of percutaneous coronary intervention and coronary artery bypass grafting.

At the most severe end of the spectrum of acute coronary syndromes is ST-segment elevation myocardial infarction (STEMI), which usually occurs when a fibrin-rich thrombus completely occludes an epicardial coronary artery. The diagnosis of STEMI is based on clinical characteristics and persistent ST-segment elevation as demonstrated by 12-lead electrocardiography. Patients with STEMI should undergo rapid assessment for reperfusion therapy, and a reperfusion strategy should be implemented promptly after the patient’s contact with the health care system. Two methods are currently available for establishing timely coronary reperfusion: primary percutaneous coronary intervention and fibrinolytic therapy. Percutaneous coronary intervention is the preferred method but is not always available. Antiplatelet agents and anticoagulants are critical adjuncts to reperfusion. This article summarizes the current evidence-based guidelines for the diagnosis and management of STEMI. This summary is followed by a brief discussion of the role of noninvasive stress testing in the assessment of patients with acute coronary syndrome and their selection for coronary revascularization.


Unlikely unstable angina/non-ST-segment elevation myocardial infarction (UA/NSTEMI), ST-segment elevation myocardial infarction (STEMI) is characterized by total occlusion of the infarct-related artery. Evidence from several randomized clinical trials during the past 2 decades has established the importance of the open artery theory, which states that prompt and complete restoration of flow in the occluded artery decreases infarct size, preserves left ventricular (LV) function, and improves survival rates.1 Two types of strategies are currently available for the judicious establishment of coronary reperfusion: pharmacological (fibrinolysis) and mechanical (primary percutaneous coronary intervention [PCI]).2,3 Regardless of the mode of reperfusion, the overarching concept is to minimize total ischemic time, which is defined as the time from the onset of symptoms of STEMI to the initiation of reperfusion therapy. The 2004 STEMI guidelines from the American College of Cardiology (ACC) and the American Heart Association (AHA)4 and the 2007 focused update of these guidelines5 recommend that all patients with STEMI undergo rapid assessment for reperfusion therapy and that a reperfusion strategy be implemented promptly after the patient’s contact with the medical system. The goal is to initiate fibrinolytic therapy within 30 minutes (door-to-needle time or first medical contact–to-needle time) and to achieve intracoronary balloon inflation within 90 minutes (door-to-balloon time or first medical contact–to-balloon time) of the patient’s arrival at the hospital or first contact with the medical system.

REPERFUSION THERAPY

FIBRINOLYSIS

An overview of the results of 9 trials by the Fibrinolytic Therapy Trialists’ Collaborative Group comparing the outcomes of patients undergoing fibrinolytic therapy and those of controls demonstrated statistically significant absolute reductions in 35-day mortality rates of approximately 30 per 1000 for patients who arrived at the hospital within 6 hours of the onset of symptoms and of approximately 20 per
1000 for patients who arrived 7 to 12 hours after the onset of symptoms. Benefit was observed among patients with ST-segment elevation or left bundle branch block (LBBB) at the time of presentation, irrespective of age, sex, blood pressure, heart rate, or a history of myocardial infarction (MI) or diabetes. The greatest benefit was observed among patients with LBBB or anterior STEMI (Figure 1). Fibrinolytic therapy is currently indicated, in the absence of contraindications (Table 1), for patients with STEMI who have experienced symptom onset within the previous 12 hours and in whom electrocardiography (ECG) demonstrates ST-segment elevation of more than 0.1 mV in at least 2 contiguous precordial leads or at least 2 adjacent limb leads, or new or presumably new LBBB.

The fibrinolytic agents currently approved for treating patients with STEMI include streptokinase, alteplase, reteplase, and tenecteplase (Table 2). The TIMI (Thrombolysis in Myocardial Infarction), phase 1 trial randomly assigned 290 patients with evolving acute MI to alteplase (the first tissue plasminogen activator to be produced through recombinant DNA technology) or to streptokinase. Alteplase was far superior in achieving coronary reperfusion; twice as many occluded infarct-related arteries opened after 90 minutes with alteplase than with streptokinase.

### TABLE 1. Contraindications and Cautions for Fibrinolysis as Treatment for Patients With ST-Segment Elevation Myocardial Infarction

<table>
<thead>
<tr>
<th>Absolute contraindications</th>
<th>Relative contraindications</th>
</tr>
</thead>
<tbody>
<tr>
<td>Any previous ICH</td>
<td>History of chronic, severe, poorly controlled hypertension</td>
</tr>
<tr>
<td>Known structural cerebrovascular lesion (eg, arteriovenous malformation)</td>
<td>Severe uncontrolled hypertension on presentation (SBP ≥180 mm Hg or DBP ≥110 mm Hg)</td>
</tr>
<tr>
<td>Known malignant intracranial neoplasm (primary or metastatic)</td>
<td>History of ischemic stroke more than 3 mo previously, dementia, or known intracranial pathology not included in contraindications</td>
</tr>
<tr>
<td>Ischemic stroke within 3 mo, except for acute ischemic stroke within 3 h</td>
<td>Traumatic or prolonged (&gt;10 min) CPR or major surgery (&lt;3 wk previously)</td>
</tr>
<tr>
<td>Suspected aortic dissection</td>
<td>Recent (within 2-4 wk) internal bleeding</td>
</tr>
<tr>
<td>Active bleeding or bleeding diathesis (excluding menses)</td>
<td>Noncompressible vascular punctures</td>
</tr>
<tr>
<td>Severe closed-head or facial trauma within 3 mo</td>
<td>For streptokinase/antiplase: previous exposure (&gt;5 d previously)</td>
</tr>
<tr>
<td>Pregnancy</td>
<td>or previous allergic reaction to these agents</td>
</tr>
</tbody>
</table>

CPR = cardiopulmonary resuscitation; DBP = diastolic blood pressure; ICH = intracerebral hemorrhage; INR = international normalized ratio; SBP = systolic blood pressure.

From *J Am Coll Cardiol,* with permission from Elsevier.

### TABLE 2. Properties of Approved Fibrinolytic Agents

<table>
<thead>
<tr>
<th>Fibrinolytic agent</th>
<th>Streptokinase</th>
<th>Alteplase</th>
<th>Reteplase</th>
<th>Tenecteplase</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mean plasma half-life (min)</td>
<td>Unavailable</td>
<td>3.5</td>
<td>14</td>
<td>17</td>
</tr>
<tr>
<td>Mean plasma clearance (mL/min)</td>
<td>Unavailable</td>
<td>572</td>
<td>283</td>
<td>151</td>
</tr>
<tr>
<td>Mode of administration</td>
<td>Infusion for 30-60 min</td>
<td>Bolus + infusion for 90 min</td>
<td>Double bolus 30 min apart</td>
<td>Single bolus</td>
</tr>
<tr>
<td>Weight-adjusted dosing</td>
<td>No</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
</tr>
<tr>
<td>Dose</td>
<td>1.5 mega units</td>
<td>≤100 mg&lt;sup&gt;a&lt;/sup&gt; 10 U + 10 U</td>
<td>30-50 mg&lt;sup&gt;b&lt;/sup&gt;</td>
<td></td>
</tr>
<tr>
<td>Fibrin specificity&lt;sup&gt;c&lt;/sup&gt;</td>
<td>None</td>
<td>++</td>
<td>+</td>
<td>+++</td>
</tr>
<tr>
<td>Thrombosis in Myocardial Infarction grade 3 flow at 90 min (% of patients)</td>
<td>32</td>
<td>54</td>
<td>60</td>
<td>63</td>
</tr>
<tr>
<td>Cost per dose ($)</td>
<td>613</td>
<td>2974</td>
<td>2750</td>
<td>2833 for 50 mg</td>
</tr>
</tbody>
</table>

<sup>a</sup> Bolus = 15 mg; infusion = 0.75 mg/kg for 30 min (maximum, 50 mg), then 0.5 mg/kg (maximum, 35 mg) for the next 60 min, to an overall maximum of 100 mg.

<sup>b</sup> The weight-adjusted doses were as follows: ≤60 kg, 30 mg; 60-69 kg, 35 mg; 70-79 kg, 40 mg; 80-89 kg, 45 mg; and ≥90 kg, 50 mg.

<sup>c</sup> Semiquantitative scale based on depletion of fibrinogen and other measures of systemic anticoagulation.
GUSTO (Global Utilization of Strategies to Open Occluded Arteries)-I trial, which involved more than 40,000 patients, compared the clinical efficacy of accelerated alteplase with that of streptokinase. The 30-day mortality rates were significantly lower with accelerated alteplase (6.3%) than with streptokinase (7.3%; relative risk reduction, 14%; \( P = .001 \)).

Newer fibrin-specific lytic agents have longer half-lives and can be administered as bolus agents; although these agents have demonstrated no further improvements in survival, they offer the convenience of easier administration and can be delivered more rapidly in the emergency department. The GUSTO-III trial found no significant difference in 30-day mortality rates among patients treated with reteplase (7.47%) and those treated with accelerated alteplase (7.24%; \( P = .54 \)).

Tenecteplase therapy was assessed in the ASSENT (Assessment of the Safety of a New Thrombolytic)-2 trial, which randomly assigned 16,949 patients to weight-based single-bolus tenecteplase or to accelerated alteplase infusion. The 30-day mortality rates were virtually identical; this outcome met the predefined criteria for equivalence. As a single-bolus agent, tenecteplase has become the most widely used fibrin-specific agent.

**Primary PCI**

A meta-analysis of 23 randomized clinical trials that compared primary PCI with fibrinolytic therapy demonstrated that PCI was better than fibrinolysis in reducing the incidence of short-term and long-term adverse outcomes, including death (Figure 2). Although the clinical superiority of primary PCI is clear, the main challenge lies in the ability to implement such a strategy promptly (maintaining a first medical contact–to-balloon time of <90 minutes).

A multivariate adjusted analysis found that, for patients undergoing primary PCI, increases in the door-to-balloon time (especially by >2 hours) were associated with higher mortality rates (Figure 3).

The ACC/AHA guidelines state that the selection of either fibrinolysis or primary PCI as the appropriate reperfu-
sion strategy should depend on the clinical scenario (Table 3). Primary PCI, with or without stenting, is generally preferable if it is rapidly available because it yields better outcomes than fibrinolysis.

**Time Since Onset of Symptoms.** The effectiveness of both fibrinolytic therapy and primary PCI diminishes with the passage of time; however, the ability of PCI to produce a patent infarct-related artery is much less time-dependent. Thus, PCI is generally preferred for patients who arrive at the hospital late after the onset of symptoms (>3 hours). In contrast, clinical trials have shown that early initiation of fibrinolytic therapy (within the first 2-3 hours after the onset of symptoms) may lead to outcomes that are similar to or better than those achieved with PCI.

**TABLE 3. Assessment of Reperfusion Options for Patients With STEMI**

<table>
<thead>
<tr>
<th>Fibrinolysis is generally preferred</th>
<th>Early presentation (≤3 h from symptom onset and delay to PCI)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Primary PCI is not an option for the following reasons</td>
</tr>
<tr>
<td></td>
<td>Catheterization laboratory occupied/unavailable</td>
</tr>
<tr>
<td></td>
<td>Vascular access difficulties</td>
</tr>
<tr>
<td></td>
<td>Lack of access to a skilled PCI laboratory</td>
</tr>
<tr>
<td>Delay to primary PCI</td>
<td>Door-to-balloon time minus door-to-needle time is &gt;1 h</td>
</tr>
<tr>
<td></td>
<td>Medical contact-to-balloon time or door-to-balloon time is &gt;90 min</td>
</tr>
<tr>
<td>Primary PCI is generally preferred</td>
<td>Skilled PCI laboratory available with surgical backup</td>
</tr>
<tr>
<td></td>
<td>Medical contact-to-balloon time or door-to-balloon time is ≤90 min</td>
</tr>
<tr>
<td></td>
<td>Door-to-balloon time minus door-to-needle time is ≤1 h</td>
</tr>
<tr>
<td>High risk from STEMI</td>
<td>Cardiogenic shock</td>
</tr>
<tr>
<td>Killip class CHF ≥3</td>
<td>Contraindications to fibrinolysis, including increased risk of bleeding and ICH</td>
</tr>
<tr>
<td>Late presentation (&gt;3 h after symptom onset)</td>
<td>Diagnosis of STEMI is in doubt</td>
</tr>
</tbody>
</table>

CHF = congestive heart failure; ICH = intracerebral hemorrhage; PCI = percutaneous coronary intervention; STEMI = ST-segment elevation myocardial infarction.

From *J Am Coll Cardiol,* with permission from Elsevier.
required to transport the patient to a skilled facility is a factor in determining the appropriate strategy. According to the ACC/AHA guidelines, fibrinolytic therapy is preferable to PCI if the estimated difference between the door-to-balloon time and the door-to-needle time is greater than 1 hour.\textsuperscript{4,5}

**Contraindications to Fibrinolysis.** Primary PCI is the preferred strategy for patients with absolute or relative contraindications to fibrinolysis (Table 1). For patients who are at high risk of bleeding complications, especially intracerebral hemorrhage (ICH), PCI should be strongly considered. If PCI is unavailable, the benefit of fibrinolysis should be balanced against the risk of bleeding.

**PREHOSPITAL FIBRINOLYTIC THERAPY**

A meta-analysis of 6 randomized trials comparing prehospital and in-hospital fibrinolytic therapy for acute MI showed that prehospital fibrinolysis significantly decreased all-cause hospital mortality rates (odds ratio, 0.83; 95\% confidence interval, 0.70-0.98).\textsuperscript{24} The estimated time to fibrinolysis was 140 minutes for the prehospital group and 162 minutes for the in-hospital fibrinolysis group \textit{(P=0.007)}.

The CAPTIM (Comparison of Angioplasty and Prehospital Thrombolysis in Acute Myocardial Infarction) trial directly compared the outcomes of 840 patients treated with prehospital fibrinolysis or primary PCI within 6 hours of the onset of STEMI. The results showed no significant difference in the incidence of the primary end point (a composite of death, nonfatal reinfarction, and nonfatal disabling stroke) at 30 days between the group treated with prehospital fibrinolysis (8.2\%) and those treated with primary PCI (6.2\%).\textsuperscript{25}

The ACC/AHA guidelines state that it is reasonable to initiate prehospital fibrinolytic therapy if a physician is present in the ambulance or if the emergency medical services system provides full-time paramedics who have the equipment necessary for performing and transmitting the results of 12-lead ECG \textit{(class IIa recommendation)}.\textsuperscript{4}

**ANTI-ISCHEMIC THERAPY**

**Nitroglycerin**

Nitroglycerin (NTG) is intended primarily to relieve ischemic pain for patients with STEMI; it may also act as a vasodilator for patients with associated LV failure. The GISSI-3 (Third Gruppo Italiano per lo Studio della Sopravvivenza nell’Infarto Miocardico) trial and the ISIS-4 (Fourth International Study of Infarct Survival) trial found that NTG had no beneficial effect on mortality rates among patients with suspected MI.\textsuperscript{26,27} The standard dose of NTG is 0.4 mg, taken sublingually every 5 minutes for a total of 3 doses. If this does not relieve chest discomfort, intravenous (IV) NTG can be administered.

**Beta-Blockers**

Beta-blockers should be administered to patients with STEMI regardless of the planned reperfusion strategy. Beta-blockers decrease the rates of recurrent ischemia and reinfarction among patients receiving concomitant fibrinolytic therapy.\textsuperscript{28,29} In a recent study of patients treated with either fibrinolytic therapy or PCI, beta-blockers substantially reduced the rates of all-cause mortality, cardiovascular mortality, and recurrent nonfatal MI.\textsuperscript{30}

The 2007 update to the ACC/AHA STEMI guidelines recommends that oral beta-blocker therapy be initiated within the first 24 hours after the onset of symptoms for all patients without contraindications such as heart failure (HF), evidence of a low-output state, increased risk of cardiogenic shock, or other relative contraindications to beta-blockade, including a PR interval of more than 0.24 seconds, second- or third-degree heart block, active asthma, or reactive airway disease \textit{(class I)}.\textsuperscript{3} It is reasonable to administer IV beta-blockers to patients who are hypertensive at the time of presentation \textit{(class IIa)}. Greater caution has been suggested with the early use of IV beta-blockers, because the COMMIT (Clopidogrel and Metoprolol in Myocardial Infarction Trial) trial\textsuperscript{31} found that their use was associated with an increased risk of cardiogenic shock among patients with any of the following features: age 70 years or older, systolic blood pressure lower than 120 mm Hg, sinus tachycardia of 110 beats/min or higher, heart rate lower than 60 beats/min, or increased time since the onset of symptoms of STEMI.

**Calcium Channel Blockers**

Verapamil substantially reduced the rates of mortality and major events among patients who had MI and were not in HF.\textsuperscript{32} Diltiazem was associated with a statistically significant reduction in cardiac events at 2 years among patients without pulmonary congestion.\textsuperscript{33} The ACC/AHA guidelines state that it is reasonable to give verapamil or diltiazem to patients with STEMI for whom beta-blockers are ineffective or contraindicated for relief of ongoing ischemia or control of heart rate.

**ANALGESIA**

The updated guidelines contain a class I recommendation for the use of morphine in managing the pain associated with STEMI; however, for the pain associated with UA/NSTEMI, the recommendation for morphine has been downgraded to class IIa. The administration of nonsteroidal anti-inflammatory drugs (both nonselective and cyclooxygenase-2 selective agents, except for aspirin) should be discontinued when a patient presents with STEMI, and these drugs should be avoided during the period of hospitalization because they are associated with cardiovascular risks.\textsuperscript{3}
of a rapid ventricular response (with atrial fibrillation or atrial flutter) in the absence of CHF, LV dysfunction, or atrioventricular block (class IIa recommendation). The dihydropyridine calcium antagonist nifedipine (immediate-release form) is contraindicated for patients with STEMI. The newer dihydropyridines (eg, amlodipine) have not been tested for patients with STEMI.

**Inhibitors of the Renin-Angiotensin-Aldosterone System**

Several large randomized trials of angiotensin-converting enzyme (ACE) inhibitors administered to patients with STEMI, as well as a meta-analysis, have found statistically significant decreases in mortality rates. The greatest reduction in the mortality rate occurred within the first 5 days after an MI; this finding underscores the importance of early treatment. The ACC/AHA guidelines recommend the administration of an oral ACE inhibitor within the first 24 hours after an MI to patients with anterior STEMI, pulmonary congestion, or an LV ejection fraction (LVEF) of less than 40%, in the absence of hypotension or other known contraindications, such as clinically relevant renal failure, a history of bilateral stenosis of the renal arteries, or known allergy to ACE inhibitors (class I). This treatment should also be considered for patients without these features (class II). An angiotensin receptor blocker should be administered to patients with STEMI who cannot tolerate ACE inhibitors and who have either clinical or radiologic signs of HF or an LVEF of less than 40% (class I).

**Magnesium**

Although early studies suggested that magnesium might reduce the mortality rates associated with STEMI, later studies showed that it had no benefit. Intravenous magnesium is currently indicated only for patients with documented magnesium deficits and for those with torsades de pointes—type ventricular tachycardia.

**Antithrombotic Therapy**

The goals of antithrombotic therapy for patients with STEMI are to establish and maintain patency of the infarct-related artery, limit the consequences of myocardial ischemia, enhance myocardial healing, and reduce the likelihood of recurrent events. These goals can be realized with a combination of antiplatelet and anticoagulant agents, which serve as ancillary therapy to reperfusion. Aspirin is the standard antiplatelet agent. Although the latest data on clopidogrel show benefit, glycoprotein (GP) IIb/IIIa inhibitors have shown no discernible benefit to date. The 2007 update to the ACC/AHA guidelines contains a class I recommendation stating that all patients with STEMI who are undergoing reperfusion therapy (including those who receive streptokinase) should receive an anticoagulant for a minimum of 48 hours and preferably for the duration of the index hospitalization, up to 8 days. Patients with STEMI have the choice of 3 anticoagulants: unfractionated heparin (UFH), enoxaparin, and fondaparinux. For patients undergoing PCI, bivalirudin is also an option. Regimens other than UFH are recommended if anticoagulant therapy is given for more than 48 hours because prolonged treatment with UFH is associated with the risk of heparin-induced thrombocytopenia. It is reasonable to administer anticoagulants to patients who are not undergoing reperfusion (class IIa recommendation).

**Aspirin**

Aspirin should be given as early as possible to all patients with suspected STEMI, at a dose between 162 and 325 mg (to be chewed), and its administration should be continued indefinitely at a daily dose of 75 to 162 mg. The ISIS-2 (Second International Study of Infarct Survival) trial conclusively showed the efficacy of aspirin in reducing mortality rates among patients with evolving acute MI.

**Clopidogrel**

Two recent studies have provided data about the efficacy of clopidogrel in enhancing pharmacological reperfusion for patients with STEMI. The CLARITY (Clopidogrel as Adjunctive Reperfusion Therapy)-TIMI 28 trial randomly assigned 3491 patients aged 75 years or younger, who were treated with a standard fibrinolytic regimen and aspirin, to receive either clopidogrel (a 300-mg loading dose followed by 75 mg once daily) or placebo. Clopidogrel therapy was associated with a statistically significant reduction of 36% in the odds of the composite end point (an occluded infarct-related artery as demonstrated by angiography; death or recurrent MI before angiography) (clopidogrel, 15%; placebo, 21.7%; P<.001). By 30 days after the initiation of therapy, clopidogrel therapy was associated with a statistically significant reduction of 20% in the odds of the composite end point of death from cardiovascular causes, recurrent MI, or recurrent ischemia leading to the need for urgent revascularization (clopidogrel, 11.6%; placebo, 14.1%; P=.03). The rates of major bleeding and ICH were similar in the 2 groups.

In the COMMIT/CSS-2 (Second Chinese Cardiac Study) trial, 45,852 patients with suspected acute MI (93% had STEMI) were randomly allocated to 75 mg/d of clopidogrel or matching placebo. Treatment was to continue until discharge or for as long as 4 weeks in the hospital (mean, 15 days for survivors). Patients allocated to clopidogrel exhibited a statistically significant proportional reduction of 9% in the incidence of death, reinfarction, or
stroke (clopidogrel, 9.2%; placebo, 10.1%; \( P=0.02 \)) and a statistically significant proportional reduction of 7% in the incidence of death due to any cause (clopidogrel, 7.5%; placebo, 8.1%; \( P=0.03 \)). No statistically significant increase in the incidence of major bleeding was noted with clopidogrel.

The 2007 update to the ACC/AHA guidelines states that 75 mg/d of oral clopidogrel should be added to aspirin for patients with STEMI, regardless of whether they undergo reperfusion with fibrinolytic therapy or do not receive reperfusion therapy (class I recommendation). It is reasonable to administer an oral loading dose of 300 mg of clopidogrel to patients aged 75 years or younger. Treatment with clopidogrel should continue for at least 14 days (class I recommendation); long-term maintenance therapy (eg, for 1 year) is reasonable (class IIa recommendation).

Several recent studies have examined whether treatment with clopidogrel before PCI for patients with recent STEMI is superior to clopidogrel treatment initiated at the time of PCI in preventing major adverse cardiovascular events. The PCI-CLARITY study was a prospectively planned analysis of the 1863 patients who underwent PCI after mandated angiography in the CLARITY-TIMI 28 trial. Patients were randomly assigned to receive either clopidogrel or placebo initiated with fibrinolysis and given until coronary angiography, which was performed 2 to 8 days later. Patients undergoing coronary artery stenting were given open-label clopidogrel after diagnostic angiography. Overall, pretreatment with clopidogrel resulted in a statistically significant reduction of 41% in the incidence of cardiovascular death, MI, or stroke from the time of randomization through 30 days thereafter (7.5% vs 12.0%; odds ratio, 0.59; \( P=0.001 \)). No significant difference was found between groups in the rates of TIMI major or minor bleeding. Pretreatment with clopidogrel before PCI has been given a class I recommendation (level of evidence, A) by the ACC/AHA/SCAI (Society for Angiography and Interventions) PCI Guidelines. This recommendation is based on the results of the PCI-CLARITY trial, the PCI-CURE (Clopidogrel in Unstable Angina to Prevent Recurrent Events) trial, the CREDO (Clopidogrel for the Reduction of Events During Observation) trial, and a meta-analysis, which showed that clopidogrel pretreatment was associated with substantial benefits in reducing cardiovascular end points.

GLYCOPROTEIN IIb/IIIa INHIBITORS

Glycoprotein IIb/IIIa inhibitors have been combined with fibrinolytic agents in an effort to improve the likelihood of achieving TIMI 3 flow. Although initial angiographic studies showed higher TIMI 3 flow rates at 60 to 90 minutes after the administration of these agents, later clinical studies showed an increase in the incidence of bleeding complications and no advantage in terms of mortality.

The GUSTO-V trial randomly assigned 16,588 patients within 6 hours of evolving STEMI to standard-dose reteplase or half-dose reteplase and full-dose abciximab. The rate of the primary end point of 30-day mortality was similar between the 2 groups. Nonfatal in-hospital reinfarction rates were lower in the combination therapy group, but these lower rates did not translate into a survival benefit at 1 year. Combination therapy was associated with a substantial increase in major bleeding complications and an increase in ICH rates among patients older than 75 years.

The ASSENT-3 trial randomly assigned 6095 patients with STEMI to 1 of 3 tenecteplase-based regimens: full-dose tenecteplase with UFH, full-dose tenecteplase with enoxaparin, or half-dose tenecteplase plus abciximab plus weight-adjusted, reduced-dose UFH. Like the GUSTO-V trial, this trial showed that the combination of abciximab and half-dose tenecteplase was not associated with lower mortality rates than was full-dose tenecteplase; however, this combination was associated with substantially lower rates of in-hospital infarction and refractory ischemia. Notably, the rate of major bleeding (other than ICH, the rates of which were similar in the 2 groups) was substantially higher in the abciximab group.

Thus, in the absence of a benefit in mortality rates, combination pharmacological reperfusion with GP IIb/IIIa inhibitors and a half-dose fibrinolytic agent is generally not recommended. The use of GP IIb/IIIa inhibitors for patients undergoing primary PCI is discussed in “Facilitated PCI.”

UNFRACTIONATED HEPARIN

Unfractionated heparin has been the mainstay of STEMI treatment for more than 40 years. One study found that the administration of smaller dose, weight-adjusted heparin to patients with STEMI who were treated with fibrinolysis resulted in similar rates of 30-day mortality, recurrent infarction, and ICH but in lower rates of major bleeding and refractory ischemia than did the administration of heparin at doses stratified by weight. Another study found that an activated partial thromboplastin time (APTT) within a range of 50 to 70 seconds was associated with the lowest 30-day rates of mortality, stroke, and bleeding and with fewer instances of refractory ischemia than was an APTT higher than 70 seconds. The 2007 update of the ACC/AHA guidelines recommends an initial UFH bolus of 60 U/kg (maximum, 4000 U), followed by an initial infusion of 12 U/kg/h (maximum, 1000 U/h) for 48 hours after fibrinolysis, with a target APTT of 1.5 to 2 times the upper limit of normal (approximately 50-70 seconds).
**Low-Molecular-Weight Heparin**

A number of recent trials have compared low-molecular-weight heparin (LMWH) with UFH or placebo for patients with STEMI. The CREATE (Clinical Trial of Reviparin and Metabolic Modulation in Acute Myocardial Infarction Treatment Evaluation) trial randomly assigned 15,570 patients with STEMI to the subcutaneous administration of either reviparin (not currently approved in the United States) or placebo twice daily for 7 days. The incidence of the primary composite outcome of death, MI, or stroke was significantly lower with reviparin at both 7 days (reviparin, 9.6%; placebo, 11%) and 30 days (reviparin, 11.8%; placebo, 13.6%). There was a small absolute increase in the risk of life-threatening bleeding, but the benefits of therapy outweighed the risks. In the CLARITY-TIMI 28 trial, which compared LMWH and UFH, treatment with LMWH was associated with a significantly lower rate of a closed infarct-related artery or death or MI before angiography (LMWH, 13.5%; UFH, 22.5%) and with a significantly lower rate of cardiovascular death or recurrent MI through 30 days (LMWH, 6.9%; UFH, 11.5%). The rates of ICH and of major bleeding through 30 days were similar in the 2 groups. The ASSENT-3 trial found that enoxaparin plus full-dose tenecteplase achieved a significantly better outcome than UFH plus full-dose tenecteplase; the rate of mortality, in-hospital reinfarction, or in-hospital refractory ischemia was 11.4% for the enoxaparin group and 15.4% for the UFH group ($P=0.002$). A meta-analysis of 14 trials involving 25,280 patients with STEMI found that, compared with placebo, LMWH (given for 4 to 8 days) decreased the rate of reinfarction by approximately 25% and the rate of death by approximately 10%. The administration of UFH during hospitalization did not prevent reinfarction or death. The EXTRACT (Enoxaparin and Thrombolysis Reperfusion for Acute Myocardial Infarction Treatment)-TIMI 25 trial randomly assigned 20,506 patients with STEMI who were scheduled to undergo fibrinolysis to receive either enoxaparin throughout the index hospitalization or weight-based UFH for at least 48 hours. The incidence of the primary end point of death or MI through 30 days was 12.0% for the UFH group and 9.9% for the enoxaparin group (relative risk reduction, 17%; $P<0.001$). The incidence of major bleeding was higher with the enoxaparin strategy (2.1% vs 1.4%), but the net clinical benefit clearly favored enoxaparin over UFH.

**Fondaparinux**

The clinical efficacy and safety of fondaparinux was evaluated in the OASIS (Organization for the Assessment of Strategies for Ischemic Syndromes)-6 trial, which randomly assigned 12,092 patients with STEMI to receive either treatment with fondaparinux (2.5 mg/d, started early and given for up to 8 days) or usual care (placebo for those for whom UFH was not indicated, or UFH for up to 48 hours followed by placebo for up to 8 days). The composite end point of death or reinfarction at 30 days was significantly lower for patients treated with fondaparinux (9.7%) than for patients in the control group (11.2%; hazard ratio, 0.86; $P=0.008$), with an absolute risk reduction of 1.5%. Overall, bleeding was not increased, with a tendency toward fewer bleeding complications with fondaparinux. Patients undergoing primary PCI, however, exhibited a trend toward a higher rate of death or MI with fondaparinux (2.5-5.0 mg administered intravenously) than with UFH. The number of patients with catheter thrombosis was 0 in the UFH group and 22 in the fondaparinux group ($P<0.001$). The 2007 update of the ACC/AHA guidelines states that fondaparinux should not be used as the sole anticoagulant during PCI but should be coupled with an additional agent that has anticoagulant activity (such as UFH or bivalirudin) so that the risk of catheter complications can be ameliorated.

**Bivalirudin**

The HORIZONS-AMI (Harmonizing Outcomes with Revascularization and Stents in Acute Myocardial Infarction) trial randomly assigned 3602 patients with STEMI who were undergoing primary PCI to treatment with UFH plus a GP IIb/IIIa inhibitor or to treatment with bivalirudin alone. The incidence of the primary end point of net adverse clinical events, defined as death, MI, ischemic target vessel revascularization, stroke, or major bleeding at 30 days, was 24% lower in the group treated with bivalirudin alone (9.2%) than in the group receiving UFH plus a GP IIb/IIIa inhibitor (12.1%; $P=0.005$), primarily because of a 40% reduction in the rate of major bleeding (bivalirudin group, 4.9%; UFH group, 8.3%; $P<0.001$). The incidence of major adverse cardiac events was similar in the 2 groups (bivalirudin group, 5.4%; UFH group, 5.5%; $P>0.99$). After a 1-year follow-up period, the rate of cardiac-related mortality was 43% lower and the rate of all-cause mortality was 31% lower (absolute reductions, 1.7% and 1.4%) in the group receiving bivalirudin monotherapy than in the group receiving UFH plus GP IIb/IIIa inhibitors. Although the risk of acute stent thrombosis within 24 hours was higher in the bivalirudin group, no statistically significant difference was seen between the groups at 30 days and at 1 year. Thus, for patients with STEMI who are undergoing primary PCI, administering bivalirudin alone appears to reduce major bleeding complications, decrease cardiac mortality rates, and improve overall survival rates.

**Facilitated PCI**

Facilitated PCI refers to a strategy of planned immediate PCI after the administration of an initial pharmacological...
regimen aimed at improving the patency of coronary arteries before the procedure. Such regimens have included GP IIb/IIIa inhibitors, full-dose or reduced-dose fibrinolytic therapy, and the combination of a GP IIb/IIIa inhibitor and a reduced-dose fibrinolytic agent. Facilitated PCI is an attempt to capitalize on the timeliness of pharmacological reperfusion and the superior outcome of PCI. Despite the potential advantages of this strategy, clinical trials of facilitated PCI have not shown any benefit in improving outcomes.

The ASSENT-4 PCI trial randomly assigned 1667 patients with STEMI of less than 6 hours’ duration to standard PCI or PCI preceded by the administration of full-dose tenecteplase. The trial was terminated prematurely because the in-hospital mortality rate was significantly higher in the facilitated PCI group (6%) than in the standard PCI group (3%; P=.01). The primary end point, a composite of death, shock, and CHF within 90 days, was significantly higher with facilitated PCI (18.6%) than with primary PCI (13.4%; P=.0045). Patients assigned to facilitated PCI also experienced more strokes and ischemic complications than those assigned to primary PCI.

A quantitative review of 17 trials showed that, compared with primary PCI, facilitated PCI was associated with substantially higher rates of short-term mortality, nonfatal reinfarction, urgent target-vessel revascularization, total and hemorrhagic stroke, and major bleeding. The increased rates of adverse events with the facilitated approach were seen mainly in regimens based on fibrinolytic therapy, whereas no significant differences were observed in efficacy or safety between primary PCI and PCI facilitated with a GP IIb/IIIa inhibitor.

The FINESSE (Facilitated Intervention with Enhanced Reperfusion Speed to Stop Events) trial randomly assigned patients (in a 1:1:1 fashion) to early administration of combination therapy with reduced-dose reteplase and abciximab (n=828), early administration of abciximab alone followed by PCI (n=818), or abciximab alone administered just before PCI (n=806). The primary end point was the composite of all-cause mortality or complications after MI within 90 days. On arrival at the catheterization laboratory, the percentage of patients with an open artery before PCI was higher in the reteplase plus abciximab group (61%) than in the abciximab group (26%) or the primary PCI group (25%; P<.001). The percentage of patients experiencing the primary end point was 9.8% in the combination-facilitated PCI group, 10.5% in the abciximab-facilitated PCI group, and 10.7% in the primary PCI group (P=.55). TIMI major or minor bleeding occurred more often in the combination-facilitated PCI group than in either the abciximab-facilitated PCI group or the primary PCI group (P<.001).

The 2007 update of the STEMI guidelines gives a class IIb recommendation (level of evidence, C) to the selective use of a facilitated strategy with regimens other than full-dose fibrinolytic therapy for subgroups of high-risk patients when PCI is not available within 90 minutes, provided the risk of bleeding is low.

**ASSESSMENT OF REPERFUSION**

Early assessment of reperfusion is essential for determining the success of therapy. Although angiographic assessment of epicardial flow has been the criterion standard for determining the success of reperfusion, such an assessment is currently considered inadequate because studies have shown that microvascular perfusion may be impaired even when TIMI grade 3 flow and less than 50% coronary narrowing have been achieved. Furthermore, techniques that are more readily available and noninvasive are needed for assessing the early success of pharmacological reperfusion.

One such simple and readily available technique is evaluation of ECG ST-segment resolution. A resolution of more than 50% of ST-segment elevation at 60 to 90 minutes after the initiation of therapy is a good indicator of improved myocardial perfusion and is associated with enhanced recovery of LV function, reduced infarct size, and improved prognosis.

According to the ACC/AHA guidelines, it is reasonable to monitor the pattern of ST-segment elevation, cardiac rhythm, and clinical symptoms during the 60 to 180 minutes after the initiation of fibrinolytic therapy (class IIa recommendation). Noninvasive findings suggestive of reperfusion include relief of symptoms, maintenance or restoration of hemodynamic or electrical stability or both, and a reduction of at least 50% in the initial ST-segment elevation injury pattern as demonstrated by follow-up ECG 60 to 90 minutes after the initiation of therapy. In contrast, persistence of unrelenting ischemic chest pain, absence of resolution of the qualifying ST-segment elevation, and hemodynamic or electrical instability are generally indicators of failed pharmacological reperfusion and the need to consider rescue PCI.

**IMMEDIATE OR EMERGENCY INVASIVE STRATEGY AND RESCUE PCI**

*Rescue PCI* is defined as PCI within 12 hours after failed fibrinolysis for patients with continuing or recurrent myocardial ischemia. One early study, the RESCUE (Randomized Evaluation of Salvage Angioplasty with Combined Utilization of Endpoints) trial, demonstrated a lower mortality rate and decreased frequency of a composite end point of death or CHF at 30 days when PCI was performed within 8 hours of MI.
hours after the onset of symptoms for patients with anterior STEMI for whom fibrinolytic therapy had failed.66

More recently, the MERLIN (Middlesbrough Early Revascularization to Limit Infarction) trial, the REACT (Rescue Angioplasty Versus Conservative Treatment or Repeat Thrombolysis) trial, and 3 meta-analyses have re-affirmed the benefits of rescue PCI.67-71 The REACT trial involved 427 patients with acute MI for whom thrombolysis had failed (as determined by <50% resolution of ST-segment elevation on ECG at 90 minutes). Within 6 hours of pain onset, these patients were randomly assigned to repeated thrombolysis, conservative treatment, or rescue PCI.68 The primary end point was a composite of death, reinfarction, stroke, or severe HF within 6 months. The rate of event-free survival was 84.6% for patients treated with rescue PCI, 70.1% for those receiving conservative therapy, and 68.7% for those undergoing repeated thrombolysis (overall, \( P=.004 \)). The 2007 update of the STEMI guidelines gives a class I recommendation to a strategy of coronary angiography with intent to perform PCI (or emergency coronary artery bypass grafting [CABGI]) for patients with STEMI (aged <75 years) who have received fibrinolytic therapy and have cardiogenic shock, severe CHF (Killip class III), or hemodynamically compromising ventricular arrhythmias.5 It is reasonable to perform rescue PCI for patients with hemodynamic or electrical instability, persistent ischemic symptoms, or a moderate or large area of myocardium at risk (class IIa recommendation).5

### PCI AFTER SUCCESSFUL FIBRINOLYSIS OR FOR PATIENTS NOT UNDERGOING PRIMARY REPERFUSION

The “late open artery” hypothesis suggested that late patency of an infarct artery is associated with improved LV function, increased electrical stability, and the provision of collateral vessels to other coronary beds for protection against future events. The Occluded Artery Trial randomly assigned 2166 patients with a totally occluded infarct artery 3 to 28 days after MI (approximately 20% of whom received fibrinolytic therapy) to optimal medical therapy and PCI with stenting or to optimal medical therapy alone.72,73 The 4-year cumulative end point (composite of death, reinfarction, or class IV HF) was 17.2% in the PCI group and 15.6% in the medical therapy group (hazard ratio, 1.16; 95% confidence interval, 0.92-1.45; \( P=.20 \)). Reinfarction rates tended to be higher in the PCI group, and this difference may have attenuated any benefit in LV remodeling.

The 2007 update of the STEMI guidelines contains a class IIb recommendation for PCI of a hemodynamically significant stenosis in a patent infarct artery more than 24 hours after STEMI.74 Percutaneous coronary intervention of a totally occluded infarct artery more than 24 hours after STEMI is not recommended for patients with asymptomatic 1- or 2-vessel disease if they are hemodynamically and electrically stable and they exhibit no evidence of severe ischemia.

### NONINVASIVE TESTING

The goals of noninvasive testing are to determine whether ischemia is present in patients with a low or intermediate likelihood of coronary artery disease (CAD) and to estimate prognosis. High-risk patients, including those with refractory angina, hemodynamic compromise, or severe LV dysfunction, should be immediately considered for early coronary angiography and revascularization because non-invasive risk stratification would probably not differentiate a subgroup of patients with risk low enough to allow avoidance of coronary angiography. The results of noninvasive tests and the corresponding approximate mortality rates are shown in Table 4. Table 5 lists results that predict a high risk of future cardiac events. These results are derived from studies involving patients with all types of CAD. The markers of high risk, as shown, are either evidence of ischemia or LV dysfunction (either at rest or stress-induced).74,76,77

---

**TABLE 4. Noninvasive Risk Stratification**

<table>
<thead>
<tr>
<th>Risk Level</th>
<th>Definition</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>High risk</strong></td>
<td>(annual mortality rate &gt;3%)</td>
</tr>
<tr>
<td></td>
<td>- Severe resting LV dysfunction (LVEF, &lt;35%)</td>
</tr>
<tr>
<td></td>
<td>- High-risk treadmill score (score, ≥11)</td>
</tr>
<tr>
<td></td>
<td>- Severe exercise LV dysfunction (exercise LVEF, &lt;35%)</td>
</tr>
<tr>
<td></td>
<td>- Stress-induced large perfusion defect (particularly if anterior)</td>
</tr>
<tr>
<td></td>
<td>- Stress-induced multiple perfusion defects of moderate size</td>
</tr>
<tr>
<td></td>
<td>- Large, fixed perfusion defect with LV dilation or increased lung uptake (thallium-201)</td>
</tr>
<tr>
<td></td>
<td>- Stress-induced moderate perfusion defect with LV dilation or increased lung uptake (thallium-201)</td>
</tr>
<tr>
<td></td>
<td>- Echocardiographic wall-motion abnormality (involving ≥2 segments)</td>
</tr>
<tr>
<td></td>
<td>- Developing at low dose of dobutamine (&lt;10 μg/kg per min) or at a low heart rate (&lt;120 beats/min)</td>
</tr>
<tr>
<td></td>
<td>- Stress echocardiographic evidence of extensive ischemia</td>
</tr>
<tr>
<td><strong>Intermediate risk</strong></td>
<td>(annual mortality rate 1%-3%)</td>
</tr>
<tr>
<td></td>
<td>- Mild/moderate resting LV dysfunction (LVEF, 35%-49%)</td>
</tr>
<tr>
<td></td>
<td>- Intermediate-risk treadmill score (score, ≥11 to ≤15)</td>
</tr>
<tr>
<td></td>
<td>- Stress-induced moderate perfusion defect without LV dilation or increased lung intake (thallium-201)</td>
</tr>
<tr>
<td></td>
<td>- Limited stress echocardiographic ischemia with a wall-motion abnormality only at higher doses of dobutamine and involving ≤2 segments</td>
</tr>
<tr>
<td><strong>Low risk</strong></td>
<td>(annual mortality rate &lt;1%)</td>
</tr>
<tr>
<td></td>
<td>- Low-risk treadmill score (score, ≥16)</td>
</tr>
<tr>
<td></td>
<td>- Normal or small myocardial perfusion defect at rest or with stress a</td>
</tr>
<tr>
<td></td>
<td>- Normal stress echocardiographic wall motion or no change of limited resting wall-motion abnormalities during stress b</td>
</tr>
</tbody>
</table>

---

a LV = left ventricular; LVEF = LV ejection fraction.

b Although the published data are limited, patients with these findings will probably not be at low risk in the presence of either a high-risk treadmill score or severe resting LV dysfunction (LVEF, <35%).

From J Am Coll Cardiol,74 with permission from Elsevier.

---

For personal use. Mass reproduce only with permission from Mayo Clinic Proceedings.
Recent recurrence of ischemic rest pain, especially if associated with ECG changes or other signs of instability, is a contraindication to stress testing.

**TIMING OF NONINVASIVE TEST**

Noninvasive stress testing is recommended for low- or intermediate-risk patients with UA/NSTEMI who have been free of HF at rest (or with low-level activity) and free of HF for a minimum of 12 to 24 hours.\(^7^8\) One study found that, although the diagnostic and prognostic values of the results of symptom-limited exercise tests performed before discharge and after 1 month in men with UA/NSTEMI were similar, the earlier test identified patients who experienced adverse events during the first month, and this was the time during which approximately half of all events occurred during the first year.\(^7^9\) These findings illustrate the importance of early noninvasive testing for risk stratification.

The optimal time for performing stress testing after STEMI has not yet been determined. The 2004 ACC/AHA STEMI guidelines recommend that noninvasive stress testing be performed either in the hospital or early after discharge for stable patients who have not undergone coronary angiography.\(^3\)

**SELECTION OF NONINVASIVE TEST**

The ACC/AHA guidelines state that the choice of stress test should be based on the results of resting ECG, the ability to perform exercise, local expertise, and the technologies available.\(^7^8\) Exercise treadmill testing is recommended as the first-line test of choice for patients who can exercise and whose ECG results are free of baseline ST-segment abnormalities, such as resting ST-segment depression (≥0.10 mV), LV hypertrophy, bundle branch block, pre-excitation, or digoxin effect. If ST-segment abnormalities exist, an imaging modality such as nuclear imaging (single-photon emission computed tomography with either thallium-201 or technetium Tc 99m compounds as the radioactive tracer) or echocardiographic imaging should be added, and the exercise tolerance component of the test should be preserved because this test provides valuable and important prognostic information.\(^8^0\) Pharmacological stress testing (using vasodilators such as adenosine or adrenergic stimulators such as dobutamine for patients with asthma) with imaging is recommended when physical limitations (eg, arthritis, amputation, severe peripheral vascular disease, severe chronic obstructive pulmonary disease, or general debility) preclude adequate exercise stress. Although stress myocardial perfusion imaging or stress echocardiographic imaging is slightly more sensitive than ECG stress testing alone and has greater prognostic value,\(^8^1,8^2\) it is generally cost-effective only for higher-risk patients.\(^8^3\) Neither single-photon emission computed tomography nor echocardiography has proved superior for the purpose of risk stratification for patients with acute coronary syndrome (ACS). Resting echocardiography can, however, evaluate local and global LV function and can detect complications of MI, such as mural thrombi, aneurysms, valvular dysfunction, ventricular septal rupture, and pericardial effusion. For women, the optimal testing strategy is less well defined than that for men, but evidence suggests that imaging studies are superior to exercise ECG evaluation.\(^8^4\)

Cardiac magnetic resonance imaging and coronary computed tomographic angiography (CCTA) are newer imaging modalities that hold promise as alternative or supplementary imaging modalities for assessing patients who present with chest pain syndromes.\(^8^5,8^6,8^7\) Cardiac magnetic resonance imaging can assess cardiac function, perfusion, and viability in the same setting. Coronary computed tomographic angiography provides valuable anatomic information and has a high negative predictive value; that is, if no evidence of either calcified or noncalcified (soft/fibrous) plaque is found, then it is highly unlikely that the patient’s symptoms are the result of ACS.\(^8^5,8^6,8^8\) The disadvantages of CCTA are exposure to a high dose of radiation (8–24 mSv) and the absence of a functional or physiologic assessment. The 2007 ACC/AHA UA/NSTEMI guidelines recommend CCTA as a reasonable alternative to stress testing for patients with negative results from 12-lead ECG and cardiac biomarker tests and a low or intermediate probability of CAD (class IIa recommendation).

Patients with definite ACS who are not scheduled for coronary angiography and left ventriculography should have their LV function assessed by echocardiography or another imaging modality because LV function is a powerful determinent of prognosis and greatly affects therapeutic options.\(^8^9,9^0\)
SELECTION FOR CORONARY ANGIOGRAPHY

The results of stress testing should be discussed with the patient (or family) and used to help determine the advisability of coronary angiography. Patients for whom noninvasive stress testing yields high-risk findings should be referred for coronary angiography and revascularization. The VANQWISH (Veterans Affairs Non-Q-Wave Infarction Strategies In-Hospital) trial used the results of symptom-limited thallium exercise treadmill testing at 3 to 5 days after MI to direct the need for angiography among 442 patients with non–Q-wave MI who were randomly assigned to an early conservative treatment strategy.91 Among patients who met the VANQWISH stress test criteria for coronary angiography, 51% were found to have surgical CAD and showed favorable outcomes after revascularization.92 Similarly, a benefit of revascularization was found for patients with ischemia demonstrated by stress testing after thrombolytic therapy for STEMI.93 Angiography provides detailed structural information that helps in determining prognosis and directing further revascularization plans (either PCI or CABG); when combined with LV angiography, it allows an assessment of global and regional LV function.

CORONARY REVASCUlarIZATION

Coronary revascularization (PCI or CABG) is performed to improve prognosis, relieve symptoms, prevent ischemic complications, and improve functional capacity. Important factors that must be considered when proceeding from diagnostic angiography to revascularization are coronary anatomy, ventricular function, anticipated life expectancy, comorbid conditions, functional capacity, severity of symptoms, and quantity of viable myocardium at risk. Because of differences in the underlying pathophysiology, the indications for coronary angiography and revascularization differ for patients with UA/NSTEMI and those with STEMI.

PERCUTANEOUS CORONARY INTERVENTION

The term PCI refers to a family of percutaneous techniques that includes percutaneous transluminal coronary angioplasty, intracoronary stenting, and atheroablative technologies such as atherecetomy. Currently, 80% to 85% of PCIs involve balloon dilation and coronary stenting, whereas other devices are used for specific lesions and patient subsets. Metal stents provide the advantage of maintaining the patency of stenosed or occluded arteries and preventing restenosis. However, they constitute a powerful thrombogenic and atherogenic nidus in the vessel wall and can lead to subacute stent thrombosis and chronic complications of in-stent restenosis caused by neointimal hyperplasia and the proliferation of smooth muscle cells. To counteract this problem, investigators developed drug-eluting stents that are coated with immune modulators (most commonly sirolimus or paclitaxel). These stents arrest the cell cycle and limit local smooth muscle proliferation, thereby dramatically reducing in-stent restenosis and target vessel revascularization.94 The same mechanism delays the protective process of stent endothelialization and leads to increased rates of subacute stent thrombosis. This makes it necessary to administer thienopyridine therapy for at least 1 year and preferably longer. The 2 most commonly used drug-eluting stents are the sirolimus-coated stent and the paclitaxel-coated stent; studies have shown that these stents are equally effective.95,96

CABG VS PCI

Coronary artery bypass grafting is recommended by both the 2007 UA/NSTEMI guidelines and the 2004 STEMI guidelines as the preferred revascularization strategy for patients with significant left main disease (>50% stenosis) or with 3-vessel or 2-vessel disease with significant proximal stenosis of the left anterior descending artery and abnormal LV function (LVEF <50%) (class I recommendation).4,78 The 2007 UA/NSTEMI guidelines also state that it is reasonable to perform CABG with the internal mammary artery for patients with multivessel disease and treated diabetes mellitus (class IIa recommendation).79 In the absence of these features, either PCI (with suitable coronary anatomy) or CABG is recommended for patients with single or multivessel coronary disease who have a large or moderate area of viable myocardium and who exhibit high-risk criteria on noninvasive testing.4,78

Most of the large trials on which the current recommendations for PCI or CABG are based, however, used balloon angioplasty rather than stenting. Several recent trials have compared the outcomes achieved with PCI using stents with those achieved by CABG for patients with multivessel coronary disease. The SoS (Stent or Surgery) trial was a randomized, controlled trial comparing the outcomes achieved by these 2 procedures for 988 patients with multivessel disease. Both the initial results at a median follow-up of 2 years97 and the 6-year results98 showed a survival advantage for patients randomly assigned to CABG. In contrast, the results of a meta-analysis of 4 randomized trials that compared the outcomes achieved by CABG (n=1533) with those achieved by PCI with multiple stenting using bare-metal stents (n=1518) for patients with multivessel disease showed no statistically significant difference between the 2 groups in the primary composite end point of death, MI, and stroke or in mortality rates at 1 year after the...
initial procedures.99 The need for repeat revascularization procedures, however, remained high after PCI.

The most recent trial, SYNTAX (Synergy Between PCI With Taxus and Cardiac Surgery), randomly assigned 1800 patients with previously untreated 3-vessel or left main CAD (or both) to either PCI with drug-eluting stents or CABG.100 The rate of the primary end point (death from any cause, stroke, MI, or repeat revascularization) was significantly higher for the PCI group (17.8%; \( P=.002 \)) than for the CABG group (12.4%; \( P=.001 \)). As a result, the criterion for noninferiority was not met. At 12 months, the rates of death and MI were similar between the 2 groups. Continuous improvements in the design and composition of drug-eluting stents101 and advances in PCI technology and adjunctive therapy may render PCI equivalent to CABG for patients such as these with complex anatomy and advanced disease.

CONCLUSION

The past decade has seen enormous advances in antithrombotic therapies and catheter-based coronary interventions, and these advances have dramatically improved the outlook for patients with ACS. Patients with STEMI require immediate reperfusion therapy with either primary PCI or fibrinolysis. Primary PCI is generally preferred if intracoronary balloon inflation can be achieved within 90 minutes after the first medical contact. Cardiac stress testing has become an increasingly sophisticated and important tool for the noninvasive evaluation of patients with ACS. The debate about whether to use CABG or PCI continues, and several large randomized trials are ongoing with the goal of establishing the superiority of either revascularization strategy over the other for patients with multivessel disease.

REFERENCES


91. Boden WE, O’Rourke RA, Crawford MH, et al.; Veterans Affairs Non-Q-Wave Infarction Strategies in Hospital (VANQWISH) Trial Investigators. Outcomes in patients with acute non-Q-wave myocardial infarction randomly assigned to an invasive as compared with a conservative management strategy.


The Symposium on Cardiovascular Diseases will continue in the December issue.

This activity was designated for 1 AMA PRA Category 1 Credit(s).™

The contributions to the Symposium on Cardiovascular Diseases are now a CME activity. For CME credit, see the link on our Web site at mayoclinicproceedings.com.